Search
4D Molecular Therapeutics Inc
FDMTAdd to Watchlist
9.660USD
+0.240+2.55%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
504.94MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of 4D Molecular Therapeutics Inc is 8.18, ranking 156 out of 389 in the Biotechnology & Medical Research industry. The average price target is 33.00, with a high of 45.00 and a low of 17.00.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
28.222
Target Price
+192.16%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
4D Molecular Therapeutics Inc
FDMT
11
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is 4D Molecular Therapeutics Inc's expected revenue for the next quarter?
4D Molecular Therapeutics Inc's expected revenue is 8.00M.
What is 4D Molecular Therapeutics Inc's price target?
Analysts forecast that 4D Molecular Therapeutics Inc's price target is USD 33.00, with the highest forecast at USD 45.00 and the lowest forecast at USD 17.00.
How have 4D Molecular Therapeutics IncFDMT's recent earnings per share performed?
The market expectation was USD -1.01, while 4D Molecular Therapeutics IncFDMT's earnings per share (EPS) for the previous quarter was USD 0.30. EPS for the next quarter is expected at USD -0.87.
What is the analyst rating for 4D Molecular Therapeutics Inc?
Based on the ratings of 4D Molecular Therapeutics Inc's stock from 11 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
